1 Recommendations

1 Recommendations

1.1 The MiniMed Paradigm Veo system is recommended as an option for managing blood glucose levels in people with type 1 diabetes only if:

  • they have episodes of disabling hypoglycaemia despite optimal management with continuous subcutaneous insulin infusion and

  • the company arranges to collect, analyse and publish data on the use of the MiniMed Paradigm Veo system (see section 7.1).

1.2 The MiniMed Paradigm Veo system should be used under the supervision of a trained multidisciplinary team who are experienced in continuous subcutaneous insulin infusion and continuous glucose monitoring for managing type 1 diabetes only if the person or their carer:

  • agrees to use the sensors for at least 70% of the time

  • understands how to use it and is physically able to use the system and

  • agrees to use the system while having a structured education programme on diet and lifestyle, and counselling.

1.3 People who start to use the MiniMed Paradigm Veo system should only continue to use it if they have a decrease in the number of hypoglycaemic episodes that is sustained. Appropriate targets for such improvements should be set.

1.4 The Vibe and G4 PLATINUM CGM system shows promise but there is currently insufficient evidence to support its routine adoption in the NHS for managing blood glucose levels in people with type 1 diabetes. Robust evidence is needed to show the clinical effectiveness of using the technology in practice.

1.5 People with type 1 diabetes who are currently provided with the MiniMed Paradigm Veo system or the Vibe and G4 PLATINUM CGM system by the NHS for clinical indications that are not recommended in this NICE guidance should be able to continue using them until they and their NHS clinician consider it appropriate to stop.

During the development of this guidance, NICE became aware that a new integrated sensor‑augmented pump therapy system, the MiniMed 640G system (Medtronic), has become available. The evidence for the MiniMed 640G system has not been assessed in the guidance, and the recommendations, therefore, do not relate to its routine use in the NHS. For further information on the MiniMed 640G system please see the related NICE Medtech innovation briefing.

  • National Institute for Health and Care Excellence (NICE)